Roth Capital started coverage on Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) with a Buy rating and $3 price target. Analyst Joseph Pantginis, Ph.D., noted that Rexahn was a re-focused, re-tooled company with a clear focus on oncology drug development. He feels the company was in a state of transition during 2011 and 2012, with 2013 representing a year of putting all the pieces in place, making 2014 an important execution year for the company. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) stock opened at $1.12 in last trading session, and closed at $1.10, trading in the range of $1.08 – $1.18. The stock showed a negative weekly performance of -3.51%.
ArQule, Inc. (NASDAQ:ARQL) says DMC recommends continuation of Phase 3 trail of tivantinib. ArQule, Inc. (NASDAQ:ARQL) shares closed at $2.52 on last trade day, by gaining 6.78%. Stock 52 week range is $1.91 – $3.10. Company’s market capitalization is $158.01 billion.
Dynavax Technologies Corporation (NASDAQ:DVAX) aerage recommendation is Buy with price target of $4.50. Dynavax Technologies Corporation (NASDAQ:DVAX) stock surged 3.50% and finished the last session at $2.07. The EPS of the stock remained -0.41. Company’s market capitalization is $543.63 billion.
Pacific Biosciences of California (NASDAQ:PACB) average recommendation is Hold with average Target Price $5.63. Pacific Biosciences of California (NASDAQ:PACB) stock opened at $5.67 in last trading session and closed at $6.50. The 52 week range of the stock is $1.95 – $6.97 and the day range was $5.65 – $6.97.